Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India
Open Access
- 1 January 2026
- journal article
- Published by Asia-Pacific Blood and Marrow Transplantation Group in BLOOD CELL THERAPY / The official journal of APBMT
- Vol. 9 (2) , 77-85
Abstract
Outcomes of haploidentical transplantation have been reported to be comparable to HLA-matched transplants in several studies; however, data from low- and middle-income countries remain limited. In this retrospective study, we evaluated outcomes of 71 patients who underwent haploidentical transplantation for malignant indications using post-transplant cyclophosphamide (PTCy) between July 2010 and March 2022 and analyzed donor factors influencing outcomes. All patients received peripheral blood stem cell grafts with standard PTCy/calcineurin inhibitor/mycophenolate mofetil prophylaxis. Graft failure occurred in seven patients (9.8%), with a higher incidence observed in those with 0-1 mismatch in the graft versus host direction (p=0.011). The incidences of grade II-IV acute graft versus host disease (GVHD) and chronic GVHD were 42.3% and 47.7%, respectively. Overall transplant related mortality (TRM) was 42.3%. Donor killer-cell immunoglobulin-like receptor haplotype BX with 2DS2 and the Bw6Bw6 ligand in recipients were associated with a reduced risk of relapse. The 5-year overall survival was 31.9%. On multivariate analysis, female donors were associated with improved overall survival (hazard ratio 0.465 [95% confidence interval 0.222-0.974], p=0.042). Transplant outcomes were primarily limited by a high incidence of TRM. These findings warrant validation in larger multicenter studies.Keywords
This publication has 26 references indexed in Scilit:
- Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody responseTransfusion, 2013
- T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor TransplantationJournal of Clinical Oncology, 2013
- Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemiaBlood, 2009
- Survival after T cell–depleted haploidentical stem cell transplantation is improved using the mother as donorBlood, 2008
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?Blood, 2004
- Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical siblingBlood, 2002
- Major-Histocompatibility-Complex Class I Alleles and Antigens in Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2001
- Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal graftsBone Marrow Transplantation, 2001
- Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donorsTransfusion Science, 1994